There are dozens of FDA-approved peptide drugs, and some of them have been on the market for a century. Insulin predates the modern approval framework entirely.
But almost every version of this question that gets typed into a search bar is really asking something else: whether a specific compound someone has read about is approved, and by extension whether the material being sold under that compound’s name is legitimate. Those are two different questions, and the gap between them is where most of the confusion in this category lives.
This post answers both. First, what an FDA approval of a peptide drug actually covers. Then a catalog of the well-established approved peptide drugs by class. Then the part that most write-ups skip: what happens when a research compound shares a molecule name with an approved drug, and what carries over. The short answer to that last one is nothing.
Everything below describes regulatory status. Nothing here is medical, dosing, or safety guidance, and nothing here is a recommendation about any product.
What FDA approval of a peptide drug actually means
An approval is not granted to a molecule. This is the single most misunderstood thing in the category, and it explains almost every downstream error.
The FDA approves a specific formulation, manufactured by a specific sponsor under a specific set of controls, for a specific indication, at a specific set of parameters, in specific packaging, with specific labeling. The approval document names all of it. Change the sponsor, change the manufacturing process, change the indication, or change the formulation, and you are outside the approval and back at the beginning of a regulatory pathway.
That is why the same molecule can appear under multiple brand names with separate approvals. Semaglutide is approved as Ozempic and as Wegovy and as Rybelsus. Those are three approvals, three formulations, three indications, one molecule. The molecule itself holds no status.
It is also why “FDA approved” is close to meaningless as a phrase attached to a raw compound. There is no such thing as an approved chemical in the abstract. There is only an approved product.
A few related terms get used interchangeably and should not be:
| Term | What it actually means |
|---|---|
| FDA approved | A specific product, from a named sponsor, cleared for a named indication after review of safety and efficacy data |
| FDA registered | The facility filed a registration. Says nothing about the product |
| GRAS | A food-ingredient safety determination. A separate framework entirely, not a drug approval |
| Investigational (IND) | Cleared for study under an investigational protocol. Not approved |
| Compounded | Prepared by a pharmacy under sections 503A or 503B. Not an approved product |
| Research use only | No approval, no indication, no human-use authorization of any kind |
For the broader legal picture around that last row, see are peptides legal.
A catalog of approved peptide drugs
The list below covers well-established approvals across the main therapeutic classes. It is not exhaustive. Approval status, marketing status, and sponsors all change, so treat every date as accurate as of this writing and verify current status in the FDA’s own databases before relying on any of it.
Indications are stated as regulatory facts, meaning they describe what the approval covers. They are not claims about the compound, and they say nothing about any material sold under the same molecule name.
Metabolic and endocrine
| Molecule | Example brand | Klasse | Primary approved indications (not exhaustive; several carry later add-on indications) |
|---|---|---|---|
| Insulin and its analogs | Humulin, Lantus, Humalog, Novolog and many others | Peptide hormone | Glycemic control in diabetes mellitus |
| Semaglutid | Ozempic, Wegovy, Rybelsus | GLP-1 receptor agonist | Type 2 diabetes glycemic control (Ozempic, Rybelsus); chronic weight management (Wegovy) |
| Liraglutide | Victoza, Saxenda | GLP-1 receptor agonist | Type 2 diabetes glycemic control (Victoza); chronic weight management (Saxenda) |
| Tirzepatid | Mounjaro, Zepbound | Dual GIP and GLP-1 receptor agonist | Type 2 diabetes glycemic control (Mounjaro); chronic weight management (Zepbound) |
| Glucagon | Baqsimi, Gvoke, branded emergency formulations | Peptide hormone | Severe hypoglycemia |
Insulin deserves a note. It is the original peptide drug, in clinical use since the 1920s, and recombinant human insulin arrived in 1982. As of March 2020, insulin products in the US transitioned from being regulated as drugs to being regulated as biologics under the Biologics Price Competition and Innovation Act. So the largest peptide category by volume is now, strictly speaking, not approved under the drug pathway at all. That is a good illustration of how much regulatory nuance sits behind a simple-sounding question.
Growth hormone axis and bone
| Molecule | Example brand | Klasse | Approved indication (as written) |
|---|---|---|---|
| Tesamorelin | Egrifta | GHRH analog | Reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Approved 2010 |
| Teriparatide | Forteo | Recombinant PTH(1-34) fragment | Osteoporosis in patients at high risk of fracture. Approved 2002 |
| Calcitonin salmon | Miacalcin, Fortical | Calcitonin analog | Paget’s disease of bone, hypercalcemia, and postmenopausal osteoporosis (Miacalcin injection); Fortical carries the osteoporosis indication only |
Hormone axis modulators
| Molecule | Example brand | Klasse | Approved indication (as written) |
|---|---|---|---|
| Leuprolide | Lupron, Lupron Depot | GnRH agonist | Advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty. First approved 1985 |
| Octreotide | Sandostatin | Somatostatin analog | Acromegaly, carcinoid syndrome, VIPoma. First approved 1988 |
| Desmopressin | DDAVP | Vasopressin analog | Central diabetes insipidus and nocturnal enuresis (oral forms); certain bleeding disorders belong to the injectable and specific nasal formulations |
| Oxytocin | Pitocin | Peptide hormone | Uterine contraction in obstetric settings |
Other classes
| Molecule | Example brand | Klasse | Approved indication (as written) |
|---|---|---|---|
| Ziconotide | Prialt | Synthetic cone snail conotoxin, N-type calcium channel blocker | Severe chronic pain in patients requiring intrathecal therapy. Approved 2004 |
Ziconotide is worth including because it breaks the pattern. It is not a hormone analog or an endogenous signalling peptide. It is a synthetic version of omega-conotoxin MVIIA, isolated from the venom of a marine cone snail, and it is one of the clearest examples of a peptide drug that came out of natural-product chemistry rather than endocrinology.
The part that matters: approval does not travel with the molecule
Here is the failure mode this post exists to correct.
Someone reads that tesamorelin is FDA approved. That is true. Egrifta was approved in 2010. They then find tesamorelin listed as a research compound and reason that the material must therefore be an approved drug, or at least an approved-adjacent one.
It is not. Those two things share a molecule and nothing else.
The approved product is a specific formulation from a named sponsor, manufactured under process controls filed with the agency, packaged and labeled according to the approval, and cleared for one narrow indication. A research-grade compound with the same molecule name is a laboratory article. It carries:
- No approval
- No indication
- No human-use authorization of any kind
- No sponsor accountable to the agency for its manufacture
- No clinical labeling
It is supplied for laboratory and research use only, and that is the whole of its regulatory status. We walked through this exact case in detail in tesamorelin vs sermorelin, where one molecule in the comparison has an approved form and the other does not, and it changes nothing about how either research article is classified.
The same logic applies in every direction. An approval held by one sponsor does not extend to another sponsor’s material. An approval for one indication does not extend to any other use. An approval for an injectable formulation does not extend to an oral one. And no approval, anywhere, extends to a compound sold as a research chemical.
If a vendor implies otherwise, that implication is the signal. It tells you what they are willing to say.
The discontinued case: sermorelin and Geref
Sermorelin is a useful example because it sits in a category people rarely account for: approved once, not marketed now.
Sermorelin acetate was approved and marketed in the United States as Geref, used in pituitary function testing and pediatric endocrinology. The marketing authorization holder withdrew it from the US market in 2008. That withdrawal was a commercial and supply decision, not a regulatory action against the compound.
The practical result is that there is no currently marketed approved sermorelin product in the US. Someone searching for whether sermorelin is FDA approved will find both “yes” and “no” in the results, and both are defensible depending on whether the answer is about historical approval or current availability. The accurate answer is: approved historically, withdrawn from the market in 2008, not currently marketed as an approved product in the US.
There are a number of peptide drugs in this state. Approval status and marketing status are separate facts, and databases that only report one of them produce exactly this kind of confusion.
Peptides that have never been approved in the US
This is the section that most vendor blogs will not write, which is the reason to write it.
A number of the most heavily researched and most heavily sold peptide compounds have no US approval at all, have never had one, and are not in any approval pathway. As of this writing that includes:
| Verbundstoff | US approval status | Additional notes |
|---|---|---|
| BPC-157 | Never approved | Placed in FDA’s compounding Category 2 in 2023, then removed from that category in April 2026 and referred for advisory committee review - a status change, not an approval. WADA lists it as prohibited |
| TB-500 / thymosin beta-4 fragment | Never approved | Followed the same compounding-review arc as BPC-157, including the April 2026 removal from Category 2. Also addressed under WADA’s prohibited categories |
| GHK-Cu | Never approved as a drug | Long history in cosmetic ingredient use, which is a separate framework from drug approval |
| Semax | Never approved in the US | Registered and marketed in Russia. Foreign registration confers nothing in the US |
| Selank | Never approved in the US | Same situation as semax |
| Ipamorelin | Never approved | Investigated historically, no approval reached |
| Melanotan-2 | Never approved | FDA has issued public warnings regarding unapproved products marketed under this name |
Two things follow from that table.
First, “never approved” is not the same as “illegal to possess or sell.” Research chemicals occupy a genuinely different regulatory position from approved drugs, and the distinction is about intended use and labeling rather than about the chemical itself. That is a longer subject, covered in are peptides legal.
Second, foreign approval does not transfer. Semax and selank are registered pharmaceuticals in Russia. That fact is real and worth knowing, and it is completely irrelevant to US regulatory status. An approval granted by another country’s regulator carries no weight with the FDA and does not make a compound approved in the US in any sense.
How to read an “FDA approved” claim on a peptide site
A short filter, in order of usefulness:
- Is a specific product named, or just a molecule? If the claim attaches to a molecule rather than a named product with a sponsor, it is not an approval claim. It is marketing.
- Is a sponsor named? Approvals belong to applicants. If nobody is named as holding it, nobody holds it.
- Is an indication stated? Approvals are always indication-bound. A claim with no indication attached is describing something other than an approval.
- Does the vendor claim the approval applies to their material? This is the disqualifying one. No vendor of research-use-only compounds holds an approval on that material, because research-use-only and approved are mutually exclusive categories.
- Can the underlying documentation be checked? Approval status is verifiable in FDA’s public databases. Product quality is a separate question, verified through the certificate of analysis, and we cover how to verify a peptide COA separately.
Common questions
Are any peptides FDA approved?
Yes, many. Insulin and its analogs, several GLP-1 receptor agonists including semaglutide and liraglutide, the dual agonist tirzepatide, tesamorelin, teriparatide, leuprolide, octreotide, calcitonin, desmopressin, oxytocin, glucagon, and ziconotide all have approved pharmaceutical forms as of this writing. In every case the approval belongs to a specific product from a specific sponsor for a specific indication, not to the molecule.
Is BPC-157 FDA approved?
No. BPC-157 has never been approved as a drug in the United States. Its compounding status has moved: FDA placed it in the Category 2 bulk-substances list in 2023, then removed it from that category in April 2026 and referred it for advisory committee review. Removal from the list is not approval, and WADA continues to list it as prohibited. Any material sold under that name is a research-use-only compound with no approval and no indication.
Why do research compounds share names with approved drugs?
Because they are the same molecule, and molecules do not have owners in that sense. Semaglutide is semaglutide whether it sits in an approved product or in a research vial. What differs is everything around the molecule: the manufacturer, the process controls, the formulation, the packaging, the labeling, the regulatory filing, and the sponsor accountable for all of it. That surrounding structure is what an approval covers, and none of it travels with a name.
If a peptide is approved somewhere else, does that count in the US?
No. Foreign regulatory approval carries no US status. Semax and selank are registered pharmaceuticals in Russia and have never been approved in the United States. Approval is jurisdiction-specific, and a marketing authorization from one regulator is not recognized by another.
Does an approved indication tell me anything about a research compound?
Only about the approved product. An indication is the outcome of a specific sponsor’s clinical program on a specific formulation, and it describes what that product was cleared for. It is not a property of the molecule and it does not describe, endorse, or apply to research-grade material of any kind. A research compound has no indication, and any vendor presenting an approved drug’s indication as a description of their product is doing something they should not be.
The honest summary
A meaningful number of peptides have approved pharmaceutical forms, and that list has grown substantially over the last fifteen years. That is a real fact about pharmacology and it is worth knowing.
It tells you nothing about research-grade compounds. Not about quality, not about legitimacy, not about status. A research compound is defined by what it lacks: no approval, no indication, no human-use authorization. The vendors worth buying from are the ones that state that plainly rather than borrowing credibility from a pharmaceutical product they have no connection to.
For the broader background on what research-grade material is and how it is specified, see what are research peptides.
All products we supply are for laboratory and research use only. Not for human consumption, ingestion, injection, or therapeutic use. Nothing in this post is medical or regulatory advice, and approval status should be verified directly in FDA’s public databases before being relied upon.